Publications by authors named "A van Biezen"
Article Synopsis
- The European Society for Blood and Marrow Transplantation (EBMT) has established a continental registry over 30 years, currently housing data on over 700,000 patients and 800,000 transplants, which supports various research and benchmarking efforts in hematopoietic cell transplantation.
- The introduction of CAR-T cell therapies, which could significantly impact blood and marrow transplantation practices, prompted EBMT to create a Cellular Therapy Form that registers CAR-T cell treated patients and collects detailed outcome data.
- The EBMT Registry received approval from the European Medicines Agency in 2019 and now holds information on more than 9,000 patients treated with CAR-T cells, facilitating analyses and evaluations of these therapies' medical value within different contexts
Article Synopsis
- - A randomized study (MC-FludT.14/L Trial II) found that fludarabine plus treosulfan (30 g/m²) is an effective and well-tolerated conditioning treatment for older patients (ages 50-70) undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- - Compared to other conditioning regimens (FluMel and BuCy), the study showed no difference in relapse rates after 2 years, but FluTreo resulted in significantly lower non-relapse mortality (NRM), indicating better tolerance.
- - Overall survival (OS) rates were higher for
We previously analyzed trends in incidence and factors associated with lethal complications in ALL/AML/CML patients (causes of deaths; COD-1 study). The objective of this study was the analysis of incidence and specific causes of death after HCT, with focus on infectious deaths in two time periods, 1980-2001 (cohort-1) and 2002-2015 (cohort-2). All patients with HCT for lymphoma, plasma cell disorders, chronic leukemia (except CML), myelodysplastic/myeloproliferative disorders, registered in the EBMT-ProMISe-database were included (n = 232,618) (COD-2 study).
View Article and Find Full Text PDFBackground: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0−100 days, 101 days−1 year, and >1 year after the first transplant.
View Article and Find Full Text PDFTransplacental trafficking of maternal and fetal cells during pregnancy establishes long-term reciprocal microchimerism in both mother and child. Consequently, the maternal immune system may become sensitized to paternal histocompatibility antigens. It has been hypothesized that mother's "exposure" to paternal HLA haplotype antigens during pregnancy may affect the outcome of hematopoietic stem cell transplantation (HSCT) when the mother serves as a donor for the child.
View Article and Find Full Text PDF